.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,399,470

« Back to Dashboard

Details for Patent: 8,399,470

Title:Inhibitors of bruton's tyrosine kinase
Abstract: Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Filing Date:Jan 30, 2012
Application Number:13/361,733
Claims:1. A compound of Formula (D) having the structure: ##STR00058## wherein: L.sub.a is CH.sub.2, O, NH, or S; Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; Y is an optionally substituted group selected from among alkyl, heteroalkyl, aryl, and heteroaryl; Z is C(.dbd.O), OC(.dbd.O), NRC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O).sub.x, or NRS(.dbd.O).sub.x, where x is 1 or 2; R is H or C.sub.1-C.sub.6alkyl; and R.sub.7 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl, substituted or unsubstituted C.sub.6-C.sub.12 arylene, or substituted or unsubstituted C.sub.3-C.sub.12 heteroarylene; R.sub.8 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl, substituted or unsubstituted C.sub.6-C.sub.12 arylene, or substituted or unsubstituted C.sub.3-C.sub.12 heteroarylene; R.sub.6 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); or R.sub.7 and R.sub.8 taken together form a bond; R.sub.6 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein L.sub.a is O.

3. The compound of claim 2, wherein Ar is phenyl.

4. The compound of claim 3, wherein Z is C(.dbd.O), NHC(.dbd.O), or S(.dbd.O).sub.2.

5. The compound of claim 4, wherein R.sub.6 and R.sub.8 are H; and R.sub.7 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl, substituted or unsubstituted C.sub.6-C.sub.12 arylene, or substituted or unsubstituted C.sub.3-C.sub.12 heteroarylene.

6. The compound of claim 5, wherein R.sub.7 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, or substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl.

7. The compound of claim 6, wherein R.sub.7 is substituted or unsubstituted C.sub.1-C.sub.4alkyl.

8. The compound of claim 7, wherein C.sub.1-C.sub.4alkyl is substituted with a disubstituted amino group.

9. The compound of claim 8, wherein R.sub.7 is ##STR00059##

10. The compound of claim 4, wherein R.sub.7 and R.sub.8 taken together form a bond; and R.sub.6 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl).

11. The compound of claim 10, wherein R.sub.6 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, or substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl.

12. The compound of claim 11, wherein R.sub.6 is ##STR00060##

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable excipient.

14. The pharmaceutical composition of claim 13 that is formulated for a route of administration selected from oral administration, parenteral administration, buccal administration, nasal administration, topical administration, or rectal administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc